Loading...
The Food and Drug Administration recently issued a safety communication about the potential for serious complications associated with transvaginally placed surgical mesh for pelvic organ prolapse (POP). This communication updates a 2008 FDA report on transvaginal mesh that was prompted by the occurrence of >1000 mesh-related adverse advents from 2005 to 2007. Since then, the FDA has received 1503 additional reports of complications associated with such POP repairs. The FDA has also conducted a review of the safety and efficacy of transvaginal mesh, leading to the conclusion that serious complications associated with surgical mesh for transvaginal repair of POP are not uncommon. Adverse events now include risk for mesh shrinkage and associat…